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Abstract
Background: Polyethyleneimine (PEI), which can interact with negatively charged DNA through electrostatic
interaction to form nanocomplexes, has been widely attempted to use as a gene delivery system. However, PEI has
some defects that are not fit for keeping on gene expression. Therefore, some modifications against PEI properties
have been done to improve their application value in gene delivery. In this study, three modified PEI derivatives,
including poly(ε-caprolactone)-pluronic-poly(ε-caprolactone) grafted PEI (PCFC-g-PEI), folic acid-PCFC-isophorone
diidocyanate-PEI (FA-PEAs) and heparin-PEI (HPEI), were evaluated in terms of their cytotoxicity and transfection
efficiency in vitro and in vivo in order to ascertain their potential application in gene therapy.
Methods: MTT assay and a marker GFP gene, encoding green fluorescent protein, were used to evaluate cell
toxicity and transfection activity of the three modified PEI in vitro. Renal cell carcinoma (RCC) models were
established in BALB/c nude mice inoculated with OS-RC-2 cells to detect the gene therapy effects using the three
PEI-derived nanoparticles as gene delivery vehicles. The expression status of a target gene Von Hippel-Lindau (VHL)
in treated tumor tissues was analyzed by semiquantitative RT-PCR and immunohistochemistry.
Results: Each of three modified PEI-derived biomaterials had an increased transfection efficiency and a lower
cytotoxicity compared with its precursor PEI with 25-kD or 2-kD molecule weight in vitro. And the mean tumor
volume was obviously decreased 30% by using FA-PEAs to transfer VHL plasmids to treat mice RCC models. The
VHL gene expression was greatly improved in the VHL-treated group. While there was no obvious tumor inhibition
treated by PCFC-g-PEI:VHL and HPEI:VHL complexes.
Conclusions: The three modified PEI-derived biomaterials, including PCFC-g-PEI, FA-PEAs and HPEI, had an
increased transfection efficiency in vitro and obviously lower toxicities compared with their precursor PEI molecules.
The FA-PEAs probably provide a potential gene delivery system to treat RCC even other cancers in future.
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Introduction
Renal cell carcinoma (RCC) is the third most common
urological cancer with an incidence of approximately 5-
10 per 100,000 and comprises 2-3% of all malignancies
[1]. The majority (~80%) type is defined as clear cell
RCC (CCRCC) which has bad prognosis and does not
sensitive to radiotherapy and chemotherapy [2,3]. There-
fore, a novel therapy strategy against CCRCC needs to
be developed. In the past decade, gene therapy was stu-
died world-widely and demonstrated as a novel method
to treat many cancers [4]. Thus, the use of gene therapy
may be a new way to treat CCRCC.
In the field of cancer gene therapy, it is well known
that the success of therapy is greatly dependent on the
gene delivery vectors which ensure the gene to reach
target cells. Recent years, cationic polymers, which can
interact with negatively charged DNA through
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widely attempted to use as gene delivery systems. The
advantages associated with this kind of vectors include
that they can protect DNA from nuclease digestion, and
thus enhance the gene expression within target cells,
they hold low immunogenic response and can also be
modified selectively, and so on [5-7]. Therefore, various
cationic polymers, such as poly(L-lysine) [8] and poly-
ethyleneimine (PEI) [9], have been synthesized and used
as a gene delivery vehicle.
Among the total non-viral gene vectors, PEI, with high
transfection efficiency, has bright prospects in application
[9,10]. However, PEI is not fit for keeping on gene
expression [10,11] due to its serious cytotoxicity. Actu-
ally, the transfection efficiency and cytotoxicity are
almost antagonistic. PEI with a low molecular weight
(MW), including 800-Da, 2000-Da MW or less, displays
a low cytotoxicity and transfection efficiency. On the
contrary, PEI with a high 25-kD MW shows higher trans-
fection efficiency and cytotoxicity [12,13]. In order to bal-
ance the transfection efficiency and toxicity, investigators
attempt to make some modifications against PEI proper-
ties. Up to now, PEI has been modified with chloroquine,
polyethylene glycol (PEG), folic acid (FA), heparin and so
on [4]. Furthermore, several PEI-based delivery vehicles
have been used to carry DNA for gene therapy [9,14,15].
For example, a liner PEI-cholesterol conjugation was
encapsulated with interleukin-12 to treat RCC mice
intravenously, which was demonstrated to be effective for
treatment of RCC-induced pulmonary metastases [15]. In
addition, folate-target gene therapy vectors have been
found to promote much higher levels of tumor-specific
gene expression than nontargeted vectors [16].
In this study, we compared cytotoxicity and the trans-
fection efficiency of the three PEI-derived materials,
including poly(ε-caprolactone)-pluronic-poly(ε-caprolac-
tone)-grafted-PEI (PCFC-g-PEI), FA-PCFC-isophorone
diidocyanate-PEI (FA-PEAs) and heparin-PEI (HPEI) in
vitro and in gene therapy carrying with Von Hippel-Lin-
dau (VHL) on mice RCC model. These new attempts
provide potential methods to treat CCRCC by VHL gene
therapy, which may have a bright prospect in future.
Methods
Cell Lines
The human CCRCC cell line OS-RC-2 and mouse macro-
phage cell line Ana-1 were purchased from the Institute of
Cell Biology, Chinese Academy of Sciences (Shanghai,
China). Human umbilical vein endothelial cell line
( H U V E C )w a so r d e r e df r o mA T C C .A l lo ft h e mw e r em a i n -
tained in RPMI-1640 media supplemented with 10% fetal
bovine serum which contained 100 units/ml of penicillin
and 100 units/ml of streptomycin. All cells were routinely
maintained at 37°C in humidified air containing 5% CO2.
Reagents
Dimethyl sulfoxide (DMSO) and 3-(4, 5-dimethylthiazol-
2-yl)-2, 5-diphenyltetrazolium bromide (MTT) were
ordered from Sigma Company, USA. The PCFC-g-PEI,
FA-PEAs and HPEI, all were synthesized. PCFC-g-PEI
was obtained by Michael addition reaction with glycidyl
methacrylate-PCFC-glycidyl methacrylate (GMA-PCFC-
GMA) and the 25-kD PEI [4]. PCFC was synthesized by
ring-opening polymerization of ε-caprolactone initiated
by pluronic 105 (poly (ethylene glycol)-poly (propylene
glycol)-poly (ethylene glycol), PEG-PPG-PEG, MW =
1900 ) [17]. The cationic HPEI nanogel was conjugated
by 2-kD PEI and heparin. Heparin is a biodegradable
negative polysaccharide with many carboxylic groups,
and PEI is a cationic polymer with many primary amine
groups in its molecular structure. Thus, in presence of
EDC/NHS, the reaction between heparin and PEI occurs
[18]. PEAs (PCFC-IPDI-PEI) were synthesized by 2-kD
PEI and PCFC copolymers using isophorone diidocya-
nate (IPDI) as a cross-linker [19]. The folic acid-coupled
PEAs were prepared by the reaction of the activated
folate ester with the amine group on the PEAs.
Evaluation of cytotoxicity of three PEI-derived materials
The cytotoxicity of the three modified PEI-derived
materials were determined by MTT assay. According to
the reported methods [20], the renal cancer cell line,
phagocytic cells and endothelial cells were used to
detect the toxicity of three modified PEI-derived materi-
als in vitro.
The OS-RC-2 cells were seeded in 96-well plates at a
d e n s i t yo f5×1 0
3 cells/well in 0.1 ml growth medium
and incubated overnight, then a series of concentrations
of each PEI-derived material (FA-PEAs, PCFC-g-PEI
and HPEI), solved in 0.1 ml fresh RPMI-1640 medium,
were respectively added into each well to incubate for
another 24 h. Untreated cells were used as a control.
Then, 20 μlo f5m g / m lM T Ts o l u t i o nw a sa d d e dt o
each well for incubation 4 h. Finally, the MTT was
removed, and 200 μl DMSO was added to dissolve the
MTT-formazan crystals. The absorbance was measured
at 490 nm by an ELISA microplate reader (Bio-Rad).
Besides that, the toxicity on Ana-1 and HUVEC cells
were evaluated with the same method. The cell viability
(%) was calculated according to the following formula.
All data were presented as the mean ± SD (Standard
Deviation).
Cell viability(%) = absorption test/absorption control × 100%
VHL- expressing plasmid
The VHL gene was cloned into the mammalian expres-
sion vector pVITRO2-neo-mcs (Invitrogen, San Diego,
CA), which can be stably transfected in mammalian
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levels. Moreover, it can also allow the ubiquitous and
constitutive co-expression of two genes of interest.
Therefore, it has usually been used as an expression vec-
tor in gene therapy [21]. The recombinant plasmid pVI-
TRO2-VHL was validated by DNA sequencing.
Transfection in vitro
In order to evaluate the transfection efficiency of the
three PEI derivatives in vitro,2μg of GFP (green fluores-
cent protein) plasmids, was respectively encapsulated
with FA-PEAs, PCFC-g-PEI and HPEI at different ratios
to transfect into OS-RC-2 cells to detect GFP expression
profiling. For FA-PEAs:GFP complexes, the weight ratio
of FA-PEAs versus GFP plasmids (pGFP) was 10:1, 20:1,
30:1 and 40:1 to optimize the transfection activity. Simi-
larly, the HPEI: GFP complex, with a gradient weight
ratio of 10:1, 15:1, 20:1 and 25:1, was utilized to transfect
OS-RC-2 cells. As a control, based on our previous stu-
dies, 2-kD PEI was used to transfer GFP into OS-RC-2
cells at 5:1 weight ratio of PEI (2-kD) versus pGFP [18].
Furthermore, the transfection effects between PCFC-g-
PEI and 25-kD PEI were also compared, and the N/P
ratio of PCFC-g-PEI versus GFP was used from 5:1, 7:1,
to 10:1. Correspondingly, the weight ratio between
PCFC-g-PEI and GFP plasmids was 0.7:1, 1:1 and 1.3:1.
This relation was acquired by the formula: N/P ratio =
7.53 × weight ratio of PEI/DNA [10]. Where N is the
number of polymer nitrogen atoms and P is the number
of DNA phosphorus atoms. As controls, same quantity
(1:1) of 25-kD PEI and GFP was used to detect transfec-
tion activity based on our previous studies [18].
OS-RC-2 cells (1 × 10
5 cells/well) were seeded on 6-
well plates to detect transfection activity. Before trans-
fection, the medium 1640 in each well was replaced
with 0.8 ml of fresh serum-free medium, then added a
different ratio of PEI: pGFP complex to mix in 0.2 ml
serum-free medium for incubation 4 h. Then the com-
plete medium 1640 was added, and the plate was main-
tained at 37°C for 24 h to observe green fluorescence
expression under Fluorescence Inverted Microscope
(IX71, OLYMPUS).
The transfection efficiency was determined based on cell
percent with GFP expressing. The number of GFP-expres-
sing cells versus the total cell quantity in the microscope
was defined as the transfection efficiency. Cell counting
was performed randomly in microscopic observation
scope under 10 × magnification with 3 repeats. All data
were presented as the mean ± standard deviation (SD).
Measurement of particle size and zeta potential of FA-
PEAs:DNA complexes
The particle size and zeta potential of the free PEI deri-
vatives and FA-PEAs:pVHL complexes were measured
by Malvern Zetasizer 3000HS (Malvern, UK) at 25°C.
Different concentration, including 1, 2, 5, 10 and 15
mg/ml of PCFC-g-PEI or FA-PEAs was separately
resolved in water to test. The FA-PEAs:pVHL com-
plexes, ranging from 5:1 to 30:1 weight ratios, were pre-
pared by adding FA-PEAs to suitable volume of VHL
plasmids to incubate at room temperature for 30 min.
Then the complexes were diluted by phosphate buffered
saline (PBS) buffer to 1 mL for measurement. Mean-
while, the particle size and zeta potential of PEI (2-kD):
pVHL complexes, at a series of ratios from 5 to 30,
were measured with the same protocol. All results were
measured three times.
RCC model and VHL-gene therapy mediated by PEI
system
The following animal experiments were in compliance
with all regulatory guidelines and were approved by the
Institutional Animal Care and Use Committee of Sichuan
University. Six to eight week-old female BALB/c nude
mice were purchased from the West China Experimental
Animal Center of Sichuan University (Sichuan, China).
Mice were permitted one week to acclimate to their
environment before studies. The CCRCC model was
established in BALB/c nude mice, inoculated with 5 ×
10
6 OS-RC-2 cells/each mouse in the right flank. Primary
tumors usually became palpable on the inoculation day
9-10 and with an average 3-mm size.
On the inoculation day 11, the tumor-bearing mice
were randomly assigned into 3 groups, including VHL-
treated, pVITRO2 and PBS group, and each group con-
tained 6 mice. The nanomaterial:DNA polyplexes were
composed of 100 μg FA-PEAs or 100 μg HPEI solved in
0.1 ml PBS and 5 μg pVITRO2-VHL plasmids, and each
mouse in the VHL-treated group was injected poly-
plexes by tail vein for 10 times at 2-days intervals. The
mice in the pVITRO2 and PBS groups were separately
injected 0.1 ml solution containing 5 μgp V I T R O 2 : 1 0 0
μgF A - P E A s( o r5μgp V I T R O 2 : 1 0 0μgH P E I ) ,a n d0 . 1
ml PBS. While, different from the FA-PEA and HPEI
system, 5 μg PCFC-g-PEI:5 μg plasmids were used to
transfer gene into a mouse based on the optimal trans-
fection activity in vitro.
Tumor size was measured with calipers before every
treatment, and tumor volumes were calculated accord-
ing to the formula: width
2 × length × 0.52. After treat-
ment for 10 times, all mice were sacrificed and tumor
tissues were collected. One part of tissues was stored
-20°C, and the other tissues were fixed in 4% formalde-
hyde solution for immunohistochemistry staining.
Semiquantitative RT-PCR
Total RNA from tumor tissues was isolated using Trizol
reagent (Invitrogen) to take as templates to amplify each
Xu et al. Journal of Translational Medicine 2011, 9:46
http://www.translational-medicine.com/content/9/1/46
Page 3 of 10target cDNA fragment, which was synthesized by using
the cDNA Synthesis Kit (#K1622, Fermentas, USA ).
The primers of VHL and b-actin for RT-PCR were
designed as following. The forward primer for VHL was
5’- TCA CCT TTG GCT CTT CAG AGA TGC A -3’
(25bp), and the reverse primer was 5’- GTC TTT CTG
CAC ATT TGG GTG GTC T -3’ (25bp). The amplified
VHL fragment was 250bp in length. The designed pri-
mers for b-actin were 5’-CGG GAA ATC GTG CGT
GAC-3’(18 bp, forward) and 5’-TGG AAG GTG GAC
AGC GAG G-3’ (19bp, reverse), and the length of the
amplified cDNA was 434 bp.
PCR was performed as follows: first cycle at 95°C for 2
min, and then 30 cycles at 94°C for 45 s, 54°C for 1 min,
72°C for 1 min and a final extension cycle of 72°C for 5
min. The house-keeping gene b-actin was taken as a
loading control. HEK293T cells were used as a positive
control in VHL expression.
Immunohistochemistry
The IHC analysis was performed mainly according to
our previous protocols [22,23]. Tumor tissue sections
with 4 μm thickness were cut from formalin-fixed and
paraffin-embedded tissues for immunohistochemistry
(IHC). The endogenous peroxidase was blocked with 3%
H2O2, and the antigen retrieval was carried out in
citrate buffer (pH6.0). The VHL expression level in
tumor tissues was detected by indirect immunohisto-
chemical staining using the labeled streptavidin-biotin
method. The anti-VHL mouse monoclonal antibodies
(Abcam, ab11191) were used as the primary antibodies,
and the second antibody was a biotinylated anti-mouse
IgG. The antigen-antibody complex was then visualized
with horseradish peroxidase-streptavidin reagents and 3,
3’-diaminobenzidine solution and counterstained with
hematoxylin.
Data statistical analysis
The SPSS program (version 15.0, SPSS Inc., USA) was
used for statistical analysis. Comparisons between two
groups were performed by Student’s t test, and compari-
sons among multiple groups were performed by One-
way ANOVA. The difference was considered significant
if p < 0.05.
Results
Cytotoxicity of three PEI derivatives
The toxicity caused by the three PEI derivatives was pri-
mary evaluated in OS-RC-2 cell line. Compared with
25-kD PEI, 10, 20 and 30 μg/ml PCFC-g-PEI had no
apparent cytotoxicity on cells. While the cell survival
rate was approximately 50% under 30 μg/ml of 25-kD
PEI incubation with cells. Therefore, the toxicity of
PCFC-g-PEI was lower than its precursor, 25-kD PEI,
for OS-RC-2 cells (Figure 1A), and the biocompatibility
of PCFC-g-PEI was improved than 25-kD PEI.
Similarly, the toxicity of FA-PEAs and HPEI on OS-
RC-2 cells was respectively compared with 2-kD PEI. As
presented in Figure 1B, with the range of 50-150 μg/ml
concentration, the toxicity was almost similar for three
nanoparticles, FA-PEAs, HPEI and 2-kD PEI. However,
the living cell number with 2-kD PEI treatment was
obviously decreased when it was increased to 200-300
μg/ml concentration. Only about half of cells were alive
with 200 μg/ml 2-kD PEI treatment, while 60% cells had
viability even exposed to more than 200 μg/ml of FA-
PEAs or HPEI. Generally, for OS-RC-2 cells, the cyto-
toxicity of FA-PEAs and HPEI was relatively lower when
compared with its precursor, 2-kD PEI.
Generally, wide varieties of in vitro assays with cells
should consistently reflect the possible physiologic
responses to nanoparticles in vivo.A c c o r d i n gt ot h e
established in vitro assessments of nanomaterial toxicity,
typically, several major cell types are used in vitro for
testing including phagocytic, epithelial, endothelial and
various cancer cell lines [20]. Therefore, besides the
renal cancer cell OS-RC-2, we further observed the toxi-
city of the three modified PEI-derived nanoparticles on
both a murine macrophage cell line, Ana-1, and a
human umbilical vein endothelial cell line (HUVEC)
respectively.
A sar e s u l t ,t h et o x i c i t yo fP C F C - g - P E Ia n dF A - P E A s
on Ana-1 and HUVEC cells was homoplastic with that
on OS-RC-2 cells. As shown in Figure 1C, the toxicity
profiling of PCFC-g-PEI on HUVEC cells was similar
with that on OS-RC-2 cells. For example, with 40 μg/ml
PCFC-g-PEI treatment on HUVEC, about 68% cells had
viability which was mimetic to 65% on OS-RC-2 cells.
Moreover, the toxicity of PCFC-g-PEI on HUVEC cells
was obviously lower when compared to the precursor
25-kD PEI. Similarly, the toxicity of FA-PEAs on
HUVEC cells was lower when compared to 2-kD PEI
(Figure 1D). When the concentration of FA-PEAs
exceeded 250 μg/ml, the percent of viable HUVEC cells
was more than 50%. On the contrary, only 28.93%
HUVEC was existent under 250 μg/ml of 2-kD PEI
treatment. Besides that, the toxicity of PCFC-g-PEI and
FA-PEAs on Ana-1 cells has homoplastic effects on OS-
RC-2 cells (data not shown).
Transfection efficiency in vitro
The GFP plasmid was used as a marker gene to detect
cell transfection activity in vitro.T h eF i g u r e2w a st h e
representative fluorescence profiling of positive GFP-
expressing cells transfected with three PEI-derived nano-
particles. For PCFC-g-PEI, the average transfection effi-
ciency was 12.1 ± 1.5%, 27.0 ± 2.1% and 7.9 ± 1.8%
corresponding to 0.7:1, 1:1 and 1.3:1 ratio of PCFC-g-
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tions, the transfection rate mediated with 25-kD PEI
was 22.6 ± 1.7%, lower than 27.0 ± 2.1% which was
transfected with PCFC-g-PEI:GFP at 1:1 weight ratio.
Therefore, when the weight ratio of PCFC-g-PEI: GFP
was 1, meanwhile, the concentration of PCFC-g-PEI was
2 μg/ml, the transfection rate of PCFC-g-PEI was high-
est and had no apparent toxicity on cells (<10 μg/ml).
Thus, PCFC-g-PEI, with the 1:1 optimized weight ratio,
had a higher transfection activity (Figure 2A-2B, Figure
3A) and a lower toxicity when compared to 25-kD PEI.
As same as PCFC-g-PEI, the transfection effect of FA-
PEAs and HPEI was also related to their weight ratio
too. As shown in Figure 2C and Figure 3B, the highest
transfection efficacy for FA-PEAs was about 18.0 ± 2.1%
at 20:1 weight ratio of FA-PEAs/GFP, while at 10:1, 30:1
and 40:1 weight ratio, there was about 6.7 ± 1.2%, 16.6
± 4.5% and 12.3 ± 1.5% cells expressing GFP respec-
t i v e l y .I na d d i t i o n ,a t2 0 : 1w e i g h tr a t i o ,4 0μg/ml FA-
PEAs showed little toxicity on OS-RC-2 cells. The simi-
lar result was also observed for HPEI, with an optimized
weight ratio of 20:1, the transfection percent was 15.5 ±
2.0%, which was close to FA-PEAs (Figure 2E, Figure
3B). Differently, the cytotoxicity of HPEI was a little
higher than FA-PEAs when the concentration was 40
μg/ml. However, the transfection efficacy with 2-kD PEI
at 5:1 weight ratio (Figure 2D-2F, Figure 3B) was about
1/3 of HPEI or FA-PEAs at 20:1.
Size and zeta potential of the FA-PEAs:pVHL complexes
We mainly measured the physic-chemical properties
(size and charge) of each separate material, including
PCFC-g-PEI and FA-PEAs, as well as the FA-PEAs:
pVHL complexes. Because PCFC-g-PEI and FA-PEAs
are amphiphilic polymers, both of them may form poly-
meric micelles through self-assembling. During the pro-
cess of the micelle formation, the concentrations of
polymers in solutions would be an important factor. As
Figure 1 Cell toxicity of several PEI-derived nanoparticles by MTT analysis. The figure A-B was shown cytotoxicity on OS-RC-2 cells, and C-
D indicated viability of HUVEC cells respectively treated with PCFC-g-PEI and FA-PEAs, which was respectively compared with 25-kD and 2-kD
PEI. The error bars represented the standard deviation of three repeated experiments (n = 3).
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vectors. The GFP expression was observed under fluorescent microscope at 10 × magnification. Figure A, C, E standed for the transfection
image that used PCFC-g-PEI, FA-PEAs and HPEI as a gene delivery vector respectively. And figure B, D and F represented the transfection image
with 25-kD PEI and 2-kD PEI as gene vectors. Figure a-f showed the transfection image which was corresponding to Figure A-F in bright field.
The scale bar represents 31.41 μm.
Figure 3 Transfection efficiency for GFP plasmid in OS-RC-2 cells mediated by the PEI and PEI-derived nanoparticles. The Figure 2A was
shown the transfection effects of PCFC-g-PEI:GFP polyplexes at different weight ratios versus the control PEI (25 kD):GFP group. The transfection
efficiency of FA-PEAs:GFP and HPEI:GFP complexes was respectively compared with the PEI (2-kD)/GFP (Figure 2B). The error bars represented the
standard deviation of experimental repeats.
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decreased obviously along with increase in its concentra-
tion. When the concentration was higher than 5 mg/ml,
the size of FA-PEAs was stable nearby 170 nm. Mean-
while, another factor, the zeta potential was lower than
30 mV when the concentration was higher than 2 mg/
ml, which indicated that the micelles may be aggregated
due to concentration increased. Moreover, the size and
zeta potential of free PCFC-g-PEI showed a same ten-
dency like as the free FA-PEAs (data not shown).
So far as FA-PEAs:pVHL complexes were concerned,
as shown in Table 2, the particle size was 277.5 nm at
the mass ratio (FA-PEAs versus pVHL) of 5, while the
particle size was below 200 nm when the FA-PEAs/
pVHL ratio exceeded 15, which indicated the plasmids
were compacted with polymers more close so that the
complexes were easier to enter into cells. Compared
with the precursor PEI (2-kD), the size of PEI:pVHL
complexes was larger than the FA-PEAs:pVHL com-
plexes obviously at same ratio. Generally, the particle
size of FA-PEAs:pVHL complexes was decreased along
with the increase of the weight ratios between FA-PEAs
and VHL plasmids due to the net positive electrostatic
repulsion between complexes. When the optimal ratio
of FA-PEAs/pVHL was 20:1, in which the transfection
rate was moderate and cytotoxicity was acceptable, the
complexes were kept stable. In addition, the average
zeta potential of FA-PEAs:pVHL complexes at 10:1 ~
30:1 mass ratio, was in the range of 7.1 to 31.6 mV,
which was a little greater than the PEI (2-kD):pVHL
complexes with 5.9 to 22.5 mV. These data indicated
that the complexes became stable along with the
increasing weight ratios. The strong positive surface
charge of polyplex is necessary for binding to the anio-
nic cell surface, which enables the entering of complexes
into cells by cellular uptake [19].
Gene therapy effects mediated by PEI-derived
nanoparticles
Based on the transfection effects of three modified PEI
in vitro, we further tested whether the PEI-derived
nanoparticles could efficiently transfer target gene into
tumor tissues in vivo. The RCC tumor xenograft was
established by inoculation with OS-RC-2 cells in nude
mice to verify VHL gene therapy effects. Compared with
the control group, the FA-PEAs:pVHL group obviously
exhibited anti-tumor activity in the tumor-bearing nude
mice from 21 to 31 days after implantation with OS-
RC-2 cells. On day 31 post-implantation, the mean
tumor volume was 678.70 ± 121.73 mm
3 in FA-PEAs:
pVHL-treated mice, whereas tumor had 935.23 ±
112.14, 950.40 ± 41.98 mm
3 in FA-PEAs:pVITRO2-trea-
ted and PBS group respectively (Figure 4, p < 0.05),
which indicated VHL gene therapy achieved about 30%
inhibiting rate of tumor growth. Whereas there was no
statistical difference between the PBS group and the FA-
PEAs:pVITRO2-treated group in tumor size. These data
indicated that the FA-PEAs:pVHL therapy can inhibit
tumor growth in vivo.
Meanwhile, the mean tumor volume in HPEI:pVHL-
treated mice was 881.12 ± 167.39 mm
3 versus 860.58 ±
124.88 mm
3 in PBS-treated group and 867.80 ± 91.18
mm
3 in HPEI:pVITRO2-treated mice. Therefore, there
was no significant difference among the three groups.
Similarly, when we used PCFC-g-PEI as gene delivery
vectors, the inhibition effect was not obvious too (data
not shown). Therefore, among the three modified PEI,
the tumor was obviously suppressed when using FA-
PEAs as a gene delivery vehicle.
VHL gene expression in tumor tissues
In order to validate the expression of target gene deliv-
ered by FA-PEAs in the tumor tissues, VHL was
detected by RT-PCR and immunohistochemistry. As
s h o w ni nt h eF i g u r e5 ,V H Lm R N Ae x p r e s s i o nw a s
increased obviously in VHL-treated group compared
with the PBS and pVITRO2 group. Three cases of
tumor tissues were performed repeatedly in each group
and obtained the same results.
Furthermore, IHC was performed to analyze the
expression and distribution of VHL protein among the
three groups. As shown in Figure 6, the VHL protein
was abundantly expressed in cytoplasm in the VHL-trea-
ted group (Figure 6C). While under same the condi-
tions, few or no expression activity was observed in the
tumor tissues in PBS group and pVITRO2 group (Figure
6A-6B). Generally, the target gene VHL was transferred
into tumor area by FA-PEAs to suppress tumor growth.
Discussion
Recently, several PEI-modified nanomaterials, as non-
viral delivery vectors, have already been extensively used
to carry DNA for gene therapy. For example, the intra-
peritoneal injection of DNA:PEI complexes is a
Table 1 The particle size and zeta potential of FA-PEAs
Concentration(mg/ml) 1 2 5 10 15
Particle size (nm) (±SD) 283.9 ± 9.4 265.7 ± 7.0 172.8 ± 5.9 187.7 ± 6.2 172.0 ± 8.1
Zeta potential (mV) (±SD) 38.2 ± 1.8 21.7 ± 1.7 14.7 ± 1.8 14.6 ± 1.9 11.1 ± 0.9
SD stands for standard deviation. All results were measured three times (n = 3).
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seminated cancer nodules that induced by pancreatic
tumor in the peritoneal cavity [9]. Moreover, one PEI
derivative, which was removed the N-acyl moieties from
commercial linear 25-kD PEI, enhanced its DNA deliv-
ery efficiency 21 times in vitro, as well as 10,000 times
in mice with a concomitant 1,500-fold enhancement in
lung specificity [24]. Another water-soluble polymer,
heparin-conjugated PEI exhibited significantly higher in
target gene expression than 25-kD PEI [25].
Due to its intrinsic transfection properties, PEI has
been used to provide the backbone of PEI-derived vec-
tor formulations. Therefore, PEI-based vector improve-
ments are needed with regard to the efficiency and
specificity of the gene transfer. In our studies, we mainly
investigated the cytotoxicity and the transfection effi-
ciency of the three PEI derivatives (PCFC-g-PEI, FA-
PEAs and HPEI) in vitro and on a RCC model in vivo.
The toxicity of three PEI derivatives was relatively lower
than their corresponding PEI precursor on OS-RC-2
tumor cells and on other cell types, including Ana-1
and HUVEC cells. The partial reasons are probably due
to the decrease in charge of complexes with decrease in
primary amine amount [4]. Meanwhile, the toxicity is
often associated with materials uptake by cells. HPEI
has a proton-buffering effect [25] and HPEI:pVHL has
higher blood compatibility and a lower cytotoxicity than
PEI (25kD):pVHL.
On the other hand, with an optimized weight ratio,
the transfection efficiency of PCFC-g-PEI is also a little
increased than 25-kD PEI. An important part of poly-
plex transfection activity depends on the polyplex phy-
sico-chemical characteristics [26]. Because the PCFC
complex contains a pluronic 105, in which the pluronic
block copolymer could enhance polycation-mediated
gene transfer in vitro [4,27]. Moreover, the particle size
of the PEI:DNA complex was also important for its
uptake by cells. For efficient endocytosis and gene trans-
fer, the complex must be small (below 200 nm) and
compact [19]. The particle size and zeta potential of the
PCFC-g-PEI:DNA and HPEI:DNA complexes had been
detected in our previous reports [4,18]. The size of
PCFC-g-PEI:DNA complexes was relatively stable
around 200 nm [4]. Therefore, when the copolymer
bind to DNA, the complexes size will be condensed
o b v i o u s l ya n dm a yb eu p t a k e ne a s i l yb yc e l l st h r o u g h
endocytosis. In the case of HPEI/DNA complexes, along
with an increase in HPEI:DNA weight ratio, the particle
size was decreased [18], which was also supported by
the FA-PEAs:pVHL polyplexes.
Similarly, the transfection efficiency of FA-PEAs and
HPEI was increased and the cytotoxicity was decreased
compared to 2-kD PEI, especially the in vivo effects of
VHL gene therapy mediated by FA-PEAs polymer were
better than other PEI-polyplexes. Except to the same
chemical structure, pluronic block copolymer, such as
PCFC-g-PEI, the poly(ε-caprolactone) (PCL) segments in
FA-PEAs can increase the circulating half-life [28],
which is contributed to enhance gene transfer efficiency
Table 2 The particle size and zeta potential of FA-PEAs:VHLpolyplexes
Weight Ratio Particle size (nm) (±SD) Zeta potential (mV) (±SD)
(Nanoparticles versus VHL plasmids
a) FA-PEAs: VHL PEI(2-kD): VHL
c FA-PEAs: VHL PEI(2-kD): VHL
c
5:1
b 277.5 ± 10.1 304.1 ± 5.7 4.4 ± 0.4 5.1 ± 0.3
10:1 238.8 ± 18.8 289.1 ± 8.9 7.1 ± 0.6 5.9 ± 0.3
15:1 182.4 ± 6.5 250.4 ± 4.6 11.4 ± 1.1 9.1 ± 0.2
20:1 165.4 ± 11.6 223.1 ± 12.5 15.6 ± 0.7 12.4 ± 0.9
25:1 143.5 ± 11.4 222.5 ± 9.3 22.4 ± 2.6 18.4 ± 0.5
30:1 140.3 ± 1.5 157.4 ± 5.1 31.6 ± 0.8 22.5 ± 0.7
SD stands for standard deviation. All data were measured three times (n = 3).
(a) The VHL plasmids were constant (2 μg), and the total volume of complexes was 1 ml.
(b) The concentration of free FA-PEAs was 10 μg/ml.
(c) The PEI (2-kD):VHL complexes were used as a control.
Figure 4 Tumor volume of RCC-bearing nude mice treated
with the FA-PEAs:VHL polyplexes. The tumor size in each group
was the mean value of six nude mice. A value of p less than 0.05
was accepted to be significant. *, p < 0.05. All the data were
presented as mean ± SEM (standard error of mean), and the
statistics were performed with Student’s t test.
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polyplexes and prolongs circulation times at the same
time [19]. In addition, the relative smaller particle size
and larger zeta potential of FA-PEAs:pVHL complexes
were also helpful for the nonspecific cell interaction
with them. Meanwhile, FA can interact with folate
receptor (FR) which is usually overexpressed in cancer
cells [29]. These resulted in its better transfection effi-
ciency in vitro and in vivo. Furthermore, both FA and
heparin could be degraded easily by enzyme in cells,
and the PEI amino group, which is harmful to cells, is
reduced too. All these factors might contribute to low
cytotoxicity of FA-PEAs and HPEI.
In order to validate the potential transport potent of the
three novel modified PEI in vivo,w eu s e dV H Lg e n e ,a
tumor suppressor gene that is usually inactivation or
absence in RCC [30], to treat the RCC model on nude
mice. The mean tumor volume in FA-PEAs:VHL-treated
mice was decreased about 30% compared to the control
group. The FR exhibits limited expression on healthy cells,
but overexpression in many types of tumors, such as ovar-
ian, colorectal and renal cell carcinomas [26,31].
Therefore, FA-PEAs:pVHL complexes could bind to FR
that locates in cell surface with nanomolar affinity. The
specific interactions between polyplexes and cell surface
are targeted via a specific ligand-receptor incorporating
mechanism, which is very important for in vivo targeting
gene therapy. And the FA-PEAs:VHL complexes might be
released into cytosol through endocytosis [32]. This is may
be the most important reason that FA-PEAs:VHL exhibits
an obvious therapeutic efficacy.
Conclusions
The three modified PEI-derived biomaterials, including
PCFC-g-PEI, FA-PEAs and HPEI, had an increased
transfection efficiency in vitro and obviously lower toxi-
cities compared with their precursor PEI with 25-kD or
2-kD molecule weight, and the gene therapy effects on
RCC model mice were obvious by using FA-PEAs:pVHL
complexes to treat tumor. Therefore, FA-PEAs may be a
potential gene transfer system to carry VHL gene to
treat RCC in future.
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